Why CNTB rose 20.9% on Sep 30 2026: phase 2 results
CNTB+20.9%on Wed Sep 30 2026
Connect Biopharma Holdings Limited Ordinary Shares was up 20.9% on the day at $1.20, ranked #2 on 1323× its usual five-minute volume, when TapeRank recorded this spike at 07:14 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 07:14 ETMOVER · PRE-MARKET
$1.20 · ▲ 20.9% ON THE DAY · 1323× 5M RVOL · RANK #2
JUSTIFIEDCONFIDENCE5/5CNTB is up 13.4% pre-market on positive Phase 2 COPD topline results showing large reductions in treatment failure and exacerbations. The statistically significant efficacy findings, favorable safety profile, and lack of a financing catalyst support the move.
WHYA 13.4% move is proportionate to a meaningful Phase 2 result with 81%-85% reductions in key outcomes, despite the small 159-patient study.ANALYZED 07:13 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 07:14 ET
LAST1.20DAY▲ 20.9%5 MIN▲ 11.08%5M RVOL1323×5M $VOL$1.4MFLOAT*63.0MRANK#2SESSIONPRE-MARKETVWAP1.12HOD1.20LOD0.9800OR HIGH—OR LOW—PREV CLOSE0.9920PM HIGH1.20PM LOW0.9800GAP▲ 16.94% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $1.89, +90.5% on the previous close of $0.9920
- 09:30 ETRegular-session high, $1.89
- 15:59 ETRegular-session low, $1.07
- 15:59 ETLast trade of the regular session, $1.10, +10.9% on the previous close of $0.9920
- Volume: 67.7M shares in regular hours, 95.7M before the open
CNTB opened at $1.89 after TapeRank read the early move as justified by positive Phase 2 COPD results for rademikibart, which significantly reduced treatment failure and exacerbations with a favorable safety profile. With no halts, the stock later reversed lower through the session, reaching a $1.07 low before ending at $1.10, still above the previous close of $0.9920. TapeRank tied the move to the company’s topline clinical results, while the SEC 8-K disclosed the event under Regulation FD and other events.
WRITTEN THU OCT 15 2026 17:58 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 07:09 ETConnect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%Benzinga
- 03:05 ET8-K — Regulation FD Disclosure; Other Events; Financial Statements and ExhibitsSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list